Evaluating quality of life after chemoradiation in anal cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the quality of life in patients with anal cancer who have undergone definitive chemoradiation. It will utilize standardized EORTC questionnaires to evaluate longitudinal quality of life, functional outcomes, oncological outcomes, and toxicity. The study will monitor both acute and late toxicities and analyze correlations between physician and patient-reported outcomes. The findings will provide insights into the overall impact of treatment on patients' lives.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* histologically proven anal cancer without distant metastases
* indication for definitive chemoradiation therapy based on multidisciplinary evaluation
* age \>=18 years
* written informed consent
* ability to answer the standardized questionaires according to the treating physician

Exclusion Criteria:

* age \< 18 years
* prior systemic therapy with regard to anal cancer
* distant metastases
* second malignancy

Where it's running

• Department of Radiation Oncology, University Hospital, LMU Munich
  Munich, Bavaria, Germany Recruiting

Study contacts

• Principal investigator: Falk Roeder, MD — Ludwig-Maximilians Universität München
• Study coordinator: Falk Roeder, MD
• Email: falk.roeder@t-online.de
• Phone: +49894400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Retifanlimab after chemoradiation for anal cancer

  This study tests whether retifanlimab can help people with anal squamous cell carcinoma who have completed chemoradiation and still have residual disease.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07927998

• Irreversible Electroporation for Recurrent Pelvic Tumors

  This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT07782164

• HPV DNA-guided chemoradiation with Retifanlimab for locally advanced anal cancer

  This study tests whether adjusting chemoradiation doses based on HPV ctDNA results and adding Retifanlimab after CRT can improve outcomes for adults with new, locally advanced anal cancer.

  Recruiting Phase 2 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07425054

• Gynecological and sexual health after radiotherapy for anal cancer.

  See if vaginal problems and changes in sexual health are linked to radiation dose in women treated with chemoradiotherapy for anal cancer 6–36 months after treatment.

  Recruiting at 3 sites Aarhus University Hospital · Aarhus and 2 other locations · NCT07296237

• Self-sampling to improve anal lesion outcomes

  This study will test whether people at higher risk for anal cancer will use a self-collected anal swab and whether that increases follow-up cytology and high-resolution anoscopy (HRA) appointment attendance.

  Recruiting at 3 sites Medical College of Wisconsin · Chicago, Illinois and 2 other locations · NCT07192055

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.